Glycemic Markers Beyond HbA1c
Dr. Yehuda Handelsman of the Metabolic Institute of America recently discussed the limitations of HbA1c as a glycemic indicator. He concluded that HbA1c “is not the most accurate measure for patients with severe kidney disease, sickle cell anemia, [and] various blood diseases.” Although continuous glucose monitoring (CGM) is also a suggested measure of diabetes outcomes, Dr. Handelsman points out that CGM is not available for many type 2 diabetics. Therefore, he proposed measuring fructosamine, glycated albumin, or advanced glycation end-products (AGEs) to better monitor type 2 diabetes.
Source: http://www.healio.com/endocrinology/diabetes/news/print/endocrine-today/%7B03a80900-36d7-48a7-8805-3b4734e25844%7D/what-metrics-should-be-considered-beyond-hba1c-to-best-measure-diabetes-outcomes Contact: Kajal Bains
Corporate Communications Associate
Epinex Diagnostics, Inc.